Acute GvHD (aGvHD) remains one of the most significant complications of allogeneic hematopoietic stem cell transplantation (HSCT) with a persistently high incidence despite a plethora of prophylactic approaches. The medical need for effective drugs to prevent aGvHD remains substantial.
Conclusions
The study shows that DF prophylaxis can reduce the incidence and severity of aGvHD in children undergoing allogeneic HSCT. This reduction observed with defibrotide is additional to standard GvHD prophylaxis that was fully implemented in these patients. Defibrotide has been reported to protect endothelial cells from damage as well as to...
Authors
Selim Corbacioglu, Simone Cesaro, Maura Faraci, Bernd Gruhn, Jaap J Boelens, Ansgar Schulz, Ingo Mueller, Jerry Stein, Robert Wynn, Johann Greil, Karl-Walter Sykora, Jacek Toporski, Petr Sedlacek, Paul G. Schlegel, Karoline Ehlert, Christine Mauz-Koerholz, Peter Bader, Elena Tudone, Maria Ballabio, Carin Heringa, Christina Peters
